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Purpose:Glioblastoma multiforme (GBM) is an aggressive primary brain tumor that is radio-
resistant and recurs despite aggressive surgery, chemo, and radiotherapy. Autotaxin (ATX)
is over expressed in various cancers including GBM and is implicated in tumor progression,
invasion, and angiogenesis. Using the ATX specific inhibitor, PF-8380, we studied ATX as a
potential target to enhance radiosensitivity in GBM.
Methods andMaterials:Mouse GL261 and Human U87-MG cells were used as GBM cell
models. Clonogenic survival assays and tumor transwell invasion assays were performed
using PF-8380 to evaluate role of ATX in survival and invasion. Radiation dependent acti-
vation of Akt was analyzed by immunoblotting. Tumor induced angiogenesis was studied
using the dorsal skin fold model in GL261. Heterotopic mouse GL261 tumors were used
to evaluate the efficacy of PF-8380 as a radiosensitizer.
Results: Pre-treatment of GL261 and U87-MG cells with 1µM PF-8380 followed by
4 Gy irradiation resulted in decreased clonogenic survival, decreased migration (33%
in GL261; P =0.002 and 17.9% in U87-MG; P =0.012), decreased invasion (35.6% in
GL261; P =0.0037 and 31.8% in U87-MG; P =0.002), and attenuated radiation-induced
Akt phosphorylation. In the tumor window model, inhibition of ATX abrogated radiation
induced tumor neovascularization (65%; P =0.011). In a heterotopic mouse GL261 tumors
untreated mice took 11.2 days to reach a tumor volume of 7000 mm3, however combina-
tion of PF-8380 (10 mg/kg) with irradiation (five fractions of 2 Gy) took more than 32 days
to reach a tumor volume of 7000 mm3.
Conclusion: Inhibition of ATX by PF-8380 led to decreased invasion and enhanced radiosen-
sitization of GBM cells. Radiation-induced activation of Akt was abrogated by inhibition of
ATX. Furthermore, inhibition of ATX led to diminished tumor vascularity and delayed tumor
growth. These results suggest that inhibition of ATX may ameliorate GBM response to
radiotherapy.
Keywords: glioblastoma, radiosensitizer, autotaxin, lysophosphatidic acid, PF-8380
INTRODUCTION
Glioblastoma multiforme (GBM), the most common primary
brain tumor, is a highly aggressive and universally fatal cancer
(1). The diffuse, invasive, and highly angiogenic characteristics
that define glioblastoma result in a high recurrence rate, despite
high-dose radiation therapy with wide margins (1–3). Following
surgical resection, the current standard of care involves adminis-
tering the DNA alkylating agent temozolomide (TMZ) concur-
rently with irradiation, followed by adjuvant TMZ (4). While
this treatment regimen does confer a survival advantage, overall
survival of patients with GBM remains abysmal at around 1 year.
Furthermore, patients without MGMT methylation only have a
marginal benefit with TMZ (4). The development of molecular
targeted therapy that increases the efficacy of radiation therapy
would potentially allow for improved local control and improved
outcomes in the treatment of GBM.
Targeting mitogenic pathways to radiosensitize GBM is under
vigorous investigation. Preclinical studies have shown vascular
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endothelial growth factor receptor (VEGFR) signaling to con-
tribute to the highly angiogenic nature of GBM (5) and VEGF
up-regulation occurs following irradiation (6, 7). Accordingly, sev-
eral drugs have targeted VEGF signaling using traps, aptamers,
and antibodies in an effort to radiosensitize GBM. Aflibercept,
a VEGF Trap, was shown to delay tumor growth in preclinical
mouse models of GBM when combined with irradiation (8). The
VEGF aptamer pegaptanib improved survival when combined
with whole brain irradiation in orthotopic mouse models for
GBM (9). VEGF inhibition with antibodies has also shown to delay
tumor growth in a greater than additive fashion in several human
cell lines in orthotopic mouse tumor models, including human
glioblastoma cell lines (7). In clinical trials, Bevacizumab, a mon-
oclonal antibody to VEGF, improves survival temporarily, but the
benefit is short lived (10). Furthermore, preliminary results of the
Phase III trial RTOG 0825 showed no improvement in overall sur-
vival when bevacizumab was added to standard chemoradiother-
apy following resection in patients with newly diagnosed GBM.
Despite these disappointing results, bevacizumab is one of the
few drugs that has shown efficacy in recurrent GBM (11). Drugs
targeting DNA repair are also under investigation. Irinotecan, a
topoisomerase I inhibitor, while having promising radiosensitiza-
tion in preclinical studies, has shown marginal improvements in
survival in clinical trials (12). ATM Kinase inhibition has also been
shown to radiosensitize glioblastoma in early preclinical studies
(13).
Small molecule protein kinase inhibitors are also being actively
investigated as GBM radiosensitizers. Vatalanib (PTK787) inhibits
VEGF, platelet derived growth factor (PDGF), and c-kit, and has
been shown to delay tumor growth when combined with irra-
diation in a colorectal cancer animal model (14). This drug is
being moved to clinical studies, showing an acceptable toxicity
profile in recently completed phase I trials in GBM (15). Enzas-
taurin, a protein kinase C inhibitor with anti-angiogenic activity,
has been shown to delay tumor progression in animal models
of GBM and is showing encouraging results in ongoing clinical
trials (16, 17).
A recent genetic analysis from the Cancer Genome Atlas
revealed that 88% of GBM has somatic alterations in the recep-
tor tyrosine kinase (RTK)/RAS/PI3K pathway (18). Gefitinib, a
drug targeting epidermal growth factor receptor (EGFR), the most
commonly mutated RTK, is being investigated as a radiosensi-
tizer in clinical trials. Unfortunately, early clinical results have
been disappointing. Recent early phase trials from the RTOG
and Mayo/North American Cancer Treatment group have shown
no survival benefit in patients receiving gefitinib with irradiation
when compared to historic controls (19, 20).
The Akt/Protein Kinase B (PKB) pathway is a central down-
stream target of the RTK/RAS/PI3K pathway. The Akt pathway
has been implicated in several cancers and supports a myriad of
cellular activities including angiogenesis, cell survival, prolifera-
tion, and migration (21). Elevated Akt and phosphorylated Akt
have not only been demonstrated in several glioblastoma cell lines
and tissue samples, but have also shown to be associated with
radioresistance (22, 23). Indeed, pharmacological inhibition of
Akt has been shown to increase radiosensitivity of glioblastoma
in vitro (23, 24). We have previously shown that irradiation of
tumor endothelium leads to increased production of cytosolic
phospholipase A2 (cPLA2), which in turn catalyzes the produc-
tion of lysophosphatidylcholine (LPC) (24). LPC can function as
a secondary messenger in a variety of signaling pathways, includ-
ing the Akt/PKB pathway (25, 26). The activation of Akt leads to
radioresistance within tumor vascular endothelium and hinders
the efficacy of radiotherapy (25–28).
Autotaxin (ATX), an enzyme with lysophospholipase D (lyso-
PLD) activity, catalyzes the production of lysophosphatidic acid
(LPA) from LPC (29–31). ATX is a 125 kDa autocrine tumor
motility enzyme and is a member of the ectonuclease pyrophos-
phatase/phosphodiesterase (NPP) family. ATX not only possesses
a lysoPLD activity, it also is a lipid carrier protein that efficiently
transports LPA to respective cognate LPA1–6 GPCRs (32). Accu-
mulating evidence points to ATX and LPA playing a role in tumor
progression, invasion, and angiogenesis (33, 34). ATX is highly
expressed in a variety of cancers including non-small cell lung
cancer (NSCLC) (35), ovarian cancer (36), breast cancer (37), and
GBM (38, 39). In GBM, ATX is preferentially expressed in actively
invading tumor cells (39). ATX overexpression in GBM is believed
to facilitate invasion and migration through endothelial cells in
an autocrine fashion as well as promote neovascularization in the
tumor core through paracrine signaling (2, 34).
Alpha-bromomethylene phosphonate (Brp-LPA), a pan LPA
receptor and ATX inhibitor, was shown to significantly enhance
radiation-induced cell death and disrupt cell invasion, cell migra-
tion, and pro-survival pathways (27, 28). Pre-treatment with
Brp-LPA prior to irradiation was shown to significantly enhance
radiation-induced cell death and disrupt cell invasion, cell migra-
tion, and pro-survival pathways.
Our previous work led us to hypothesize that inhibition of
ATX alone could effectively radiosensitize glioblastoma through
decreased production of LPA. We studied the effect of non-lipid
small molecule ATX inhibitor PF-8380 (40) in glioblastoma cells
and tumor vascular endothelial cells, using murine and human
cell lines. We found that inhibition of ATX enhances radiation
induced cell death and disrupts Akt signaling in both glioblastoma
and tumor vascular endothelial cells. We also found that inhibi-
tion of ATX inhibits migration, and decreases invasion in glioma
cell lines. Most importantly, we found that pre-treatment with
PF-8380 prior to irradiation inhibited radiation-induced angio-
genesis of tumor vascular endothelial cells and delayed progression
of glioma tumor growth in vivo. Our findings suggest that inhibi-
tion of ATX alone could serve as a potential treatment strategy to
increase the effectiveness of radiotherapy in glioblastoma.
MATERIALS AND METHODS
CELL CULTURES AND TREATMENTS
Human glioblastoma (U87-MG) cells and mouse brain microvas-
cular (bEnd.3) cells were obtained from ATCC and maintained
in RPMI 1640 with 10% fetal bovine serum (FBS) and DMEM
with 10% FBS respectively. Human Umbilical Vein Endothelial
(HUVEC) cells were obtained from Lonza and were maintained
in EGM2 media (Lonza, USA). Mouse glioma GL261 cell lines
were obtained from Dr. Yancie Gillespie (University of Alabama,
Birmingham, AL, USA) and maintained in DMEM with Nutri-
ent Mixture F-12 1:1, 10% FBS, 1% sodium pyruvate (Life
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Technologies, USA). All cells were grown in a 5% CO2 incuba-
tor at 37°C. ATX inhibitor PF-8380 (40) [6-(3-(piperazin-1-yl)
propanoyl)benzol(d)oxazol-2(3H )-one] was obtained from Pfizer
Inc. under the Pfizer–Washington University biomedical agree-
ment. The concentration of PF-8380 was calculated from the data
concerning the kinetics of inhibition of LysoPLD activity of puri-
fied ATX (40). For the radiation of cells and mice, RS2000 (Rad
Source Technologies, Inc., USA) a 160 kV x-ray machine with a
0.3 mm Cu filter was used.
QUANTITATIVE REAL-TIME PCR ANALYSIS
RNA was harvested using TRIZOL reagent per manufacturer’s
protocol (Invitrogen, Carlsbad, CA, USA). Total RNA was then
purified using the RNeasy Mini Kit (Qiagen, USA). RNA was
reverse transcribed using the high capacity cDNA Reverse Tran-
scriptase kit (Invitrogen, USA) according to the manufacturer’s
protocol. Single stranded cDNA products were then analyzed by
real-time PCR using standard commercially available TaqMan
probes from Applied Biosystems for mouse (Mm00516572_m1)
or human ATX (Hs00905125_m1) gene. Housekeeping genes of
mouse (Mm99999915_g1) or human GAPDH (Hs02758991_g1)
were used in the TaqMan Gene Expression Assay to normalize any
possible variations for the target ATX gene. Delta–delta C t relative
gene expression analysis was employed and results were compared
to either expression from U87-MG in human lines or GL261 in
mouse samples. Mean expression and standard error were cal-
culated for each group. PCR products were also run on a 1.8%
agarose gel in 1× TAE buffer stained with ethidium bromide and
visualized under UV light.
CO-CULTURE CLONOGENIC SURVIVAL ASSAY
HUVEC (1.0× 106) and bEnd.3 cells (1.0× 106) were plated in
100 mm plates and after 24 h, U87-MG (2× 106) and GL261
(2× 106) cells were plated onto transwell inserts (Corning Inc.,
USA). After co-culture for 24 h, cells were treated with 1µM of
PF-8380 or vehicle control DMSO for 45 min prior to irradia-
tion with 0, 2, 4, 6, or 8 Gy. After the treatments as co-culture
with either PF-8380 or DMSO calculated numbers of U87-MG
and GL261 cells were plated to enable normalization for plating
efficiencies. After 7 to 10 day incubation plates were fixed with
70% EtOH and stained with 1% methylene blue. Colonies con-
sisting of >50 cells were counted by viewing the plates under a
microscope. The survival fractions were calculated as (number of
colonies/number of cells plated)/(number of colonies for corre-
sponding control/number of cells plated). Survival curves were
analyzed by curve fitting to the alpha/beta model (41) calculating
D0 and n.
WOUND HEALING/SCRATCH ASSAY FOR CELL MIGRATION
GL261 or U87-MG cells were plated in triplicate onto 6 cm plates
and allowed to grow to 70% confluence. The semi-confluent cell
layer was scratched with a sterile 200µL pipette tip to create a
scratch devoid of cells and plates were washed once with PBS to
remove non-adherent cells and debris. For radiosensitization drug
studies, cells were treated with 1µM PF-8380 or DMSO for 45 min
prior to irradiation with 4 Gy, and then incubated at 37°C in 5%
CO2. Control plates were monitored for cell migration (20–24 h).
Cells were fixed with 70% ethanol and stained with 1% methyl-
ene blue. To quantify migration, cells in three randomly selected
high power fields (HPFs) in the scratched area were counted and
normalized for surrounding cell density. Mean and standard error
for each treatment group were calculated.
TUMOR TRANSWELL-INVASION ASSAYS
The tumor transwell matrigel invasion assay has previously been
used to aid in quantitation of the tumor endothelium interactions
and transmigrations (42). GL261 (1.0× 106 cells/well) or U87-
MG (0.6× 106 cells/well) were suspended in serum-free media and
added onto the upper chamber (inserts) that was matrix-coated
polycarbonate membrane filters with 8µm pores (Cell Biolabs
Inc., USA). Five hundred microliters of fresh medium was added
to the bottom chamber. For radiosensitization drug studies, both
chambers were then treated with vehicle DMSO or 1µM PF-8380
for 45 min prior to irradiation with 4 Gy. After 36 h, remaining
cells in the upper chamber of the membrane inserts were removed
using a wet cotton swab. The cells that adhered on the outer sur-
face of the transwell insert membrane which had invaded through
the matrigel were fixed with 100% methanol, and stained. Invaded
cells in 7–10 HPF from each sample were counted using Image J
Software (NIH, Bethesda, MD, USA), and the average number of
invaded cells per HPF was calculated. Mean and standard error for
each treatment group were calculated.
IMMUNOBLOT ANALYSIS
To analyze the expression of extracellular ATX protein from
endothelial and glioma cells, conditioned media from HUVEC,
bEnd.3, GL261, and U87-MG cells were collected and subse-
quently concentrated using centrifugal filter concentrators (Ami-
con). The concentrated media containing the extracellular ATX
was immunoblotted using a specific antibody to ATX (Santa Cruz,
Biotechnology, USA). In mouse and human co-culture studies,
bEnd.3 cells or HUVEC (1× 106) were plated in 10 cm well
plates and after 24 h, GL261 or U87-MG (2× 106) cells were
plated onto transwell inserts (Corning Inc., USA). After the treat-
ments total protein was extracted from treated cells using the
M-PER mammalian protein extraction reagent (Pierce, Rockford,
IL,USA). Protein concentration was quantified using BCA Reagent
(Pierce, Rockford, IL, USA) and protein extracts were analyzed
using specific antibodies to phospho-AktT308/S473 and total Akt
(Cell Signaling Technologies, Danvers, MA, USA). Antibody to
actin (Sigma, USA) was used to evaluate protein loading in each
lane. Immunoblots were developed using the Western Lightning
Chemiluminescence Plus detection system (PerkinElmer, USA)
according to the manufacturer’s protocol. Band densities were
quantitated using Image J software (NIH, Bethesda, MD, USA).
IN VIVO ANGIOGENESIS ASSAY DORSAL SKIN-FOLD CHAMBER MODEL
The implantation technique of the dorsal skin-fold chamber
model has been described previously (43). Briefly, diffusion cham-
bers containing GL261 cells (1× 106 cells per chamber) were
inserted in the dorsal air sac made by making a superficial inci-
sion horizontally along the edge of the dorsal air sac. The skin was
carefully sutured after placing the chambers underneath the skin
of each mouse. The mice treatments were performed 5–7 days fol-
lowing surgical insertion of the diffusion chambers. The skin fold
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covering the chambers was carefully removed after euthanizing the
mice and photographed under visible light. The number of tumor
induced blood vessels was counted in six to eight different fields
within the chamber in the area of the air sac fascia.
MICE, TREATMENT, AND TUMOR GROWTH DELAY
All animal procedures used in this study were approved by IACUC.
Handling of animals and housing was followed as per DCM guide-
lines. GL261 cells (1× 106) were injected into the right hind limb
of nude mice. Once tumors were palpable the mice were serpen-
tine sorted into groups of six to seven animals representing similar
distributions of tumor sizes (range= 240 mm3). Tumor bearing
mice were injected intraperitoneally with vehicle (DMSO) or PF-
8380 at 10 mg/kg body weight once daily for five consecutive days.
Forty five minutes after drug injection, mice were anesthetized
with isoflurane and positioned in the RS2000 irradiator. They
were then irradiated with 2 Gy daily for five consecutive days
for a total of 10 Gy. Lead blocks (10 mm thick) were used to
shield the head, thorax, and abdomen. Tumor size was monitored
longitudinally using an external traceable digital caliper (Fisher
Scientific, USA). Mice were sacrificed by cervical dislocation once
the tumors reached a volume of approximately 10 mm3 or when
ulceration became apparent on the hind limb per Animal Care
guidelines.
STATISTICAL ANALYSES
The mean and standard error of the mean (SEM) of each treat-
ment group were calculated for all experiments. The number of
samples is indicated in the description of each experiment. Statis-
tical analysis was done using a student’s t -test to compare two
means with P < 0.05 representing statistical significance. Non-
parametric Kruskal–Wallis test was used to compare treatment
effectiveness in the tumor growth delay experiment. All pair-
wise comparisons between treatment groups were adjusted using
Tukey’s multiple comparison method. A P-value of <0.05 was
considered statistically significant.
RESULTS
ATX IS HIGHLY EXPRESSED IN U87-MG AND GL261 GLIOBLASTOMA
CELL LINES
We analyzed the expression of ATX mRNA in GBM cell lines
(U87-MG and GL261) and endothelial cell lines (HUVEC and
bEnd.3) by quantitative real-time polymerase chain reaction (Q-
PCR). Examination of the mean∆C t values revealed significantly
higher levels of ATX expression in glioblastoma cells relative to
the corresponding endothelial cell models (U87-MG, P < 0.001;
GL261, P = 0.002) (Figure 1A). This result was confirmed further
by analyzing the PCR products on a 2% agarose gel (Figure 1B).
Quantitative analysis of the gel showed significantly higher levels of
ATX expression in glioblastoma cells relative to the corresponding
endothelial cell models (U87-MG, P < 0.001; GL261, P = 0.002).
ATX was first characterized as a 125 kDa protein in the condi-
tioned medium of human melanoma cells (44). We probed the
concentrated conditioned media of U87-MG, GL261, HUVEC,
and bEnd.3 cells by western immunoblots for extracellular ATX.
Extracellular ATX was found at higher levels in the glioblastoma
conditioned media when compared to endothelial cell conditioned
media (Figure 1C).
INHIBITION OF ATX ENHANCES RADIATION-INDUCED CELL DEATH IN
IRRADIATED U87-MG AND GL261
To determine if inhibition of ATX is sufficient to enhance radiosen-
sitivity of glioblastoma cells, we tested the efficacy of ATX inhibitor
PF-8380 in co-culture clonogenic assays designed to simulate the
tumor microenvironment. U87-MG and GL261 cells were grown
in co-culture with HUVEC and bEnd.3 respectively and treated
with 1µM PF-8380 in media containing lipid-free BSA 45 min
prior to irradiation (Figure 2). The concentration of PF-8380 was
calculated from the data concerning the kinetics of inhibition of
LysoPLD activity of purified ATX (40). Pre-treatment of GL261
and bEnd.3 with PF-8380 resulted in decreased cell survival com-
pared to cells treated with radiation alone (GL261: 6 Gy,P = 0.005;
bEnd.3: 2 Gy, P = 0.012, 4 Gy, P = 0.001, 6 Gy, P = 0.003). Sim-
ilar results were found for U87-MG and HUVEC, where pre-
treatment with PF-8380 also lead to a significant decrease in cell
survival relative to cells treated with radiation alone (U87-MG:
4 Gy, P = 0.038, 6 Gy, P = 0.008; HUVEC: 4 Gy, P = 0.033). The
curves were fitted and analyzed using the alpha/beta model (41).
There were no significant changes in the value of the extrapola-
tion numbers (n). The D0 values decreased in all four cell types
that were irradiated, confirming the conclusion reached from the
analysis of survivals at different doses, as described above. In the
mouse glioblastoma cells, the D0 decreased from 1.03 to 0.84 Gy,
while in the human cells, it decreased from 2.3 to 1.85 Gy. In
the endothelial cells, in the mouse bEnd.3 cells the D0 decreased
from 3.62 to 2.86 Gy, while in the HUVEC cells, it decreased from
1.70 to 1.19 Gy.
INHIBITION OF ATX ATTENUATES CELL MIGRATION AND CELL
INVASION IN IRRADIATED GBM CELLS
Since ATX overexpression has been previously implicated in
enhancing the invasive and migratory characteristics of glioblas-
toma cells (38, 40), we examined the effect of ATX inhibition
by PF-8380 in GL261 and U87-MG cell lines. In scratch assays
performed for GL261 we observed an 11.1% decrease in cell
migration when cells were irradiated with 4 Gy alone; however pre-
treatment with 1µM PF-8380 resulted in a 33% further reduction
in cell migration (P = 0.002) (Figure 3A). Similarly in U87-MG,
radiation alone caused a 6.1% reduction in migration, while pre-
treatment with 1µM PF-8380 reduced migration further by 17.9%
(P = 0.012) (Figure 3B). In transwell-invasion assays, we found a
significant decrease in invasion by 50% in GL261 after cells were
irradiated with 4 Gy. However, the addition of PF-8380 prior to
irradiation resulted in an additional decrease in invasion by 35.6%
(P = 0.0037) (Figure 3C). Similar results were observed in U87-
MG, where radiation alone caused a 35.6% reduction in invasion,
while pre-treatment with PF-8380 further reduced invasion by
31.8% (P = 0.002) (Figure 3D).
INHIBITION OF ATX DISRUPTS Akt SIGNALING IN GBM CELLS
ATX may activate pro-survival pathways like Akt following irra-
diation through the production of LPA. Earlier, we have shown
that inhibition of both ATX and LPA receptors with Brp-LPA
diminished Akt phosphorylation in irradiated glioblastoma and
endothelial cell lines grown in co-culture (28). We investigated
whether inhibition of ATX alone with PF-8380 could abrogate Akt
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FIGURE 1 | ATX expression in endothelial and GBM cell lines.
(A)The mRNA from endothelial cells (HUVEC and bEnd.3) as well as
tumor cells (U87-MG and GL261) were analyzed by quantitative PCR
using TaqMan probes specific for ATX. The bar graph showing the
mean ∆C t values of expression of ATX normalized to actin is shown.
(B) A representative gel indicating the mRNA levels of ATX, actin, and
GAPDH is shown. (C)The conditioned medium from endothelial cells
(HUVEC and bEnd.3) and tumor cells (U87-MG and GL261) was
concentrated and then were immunoblotted and probed with an anti
ATX antibody.
phosphorylation following irradiation. Glioblastoma (GL261 or
U87-MG) cells were grown in co-culture with endothelial cells
(bEnd.3 or HUVEC). These co-cultures were then treated with
1µM PF-8380 or vehicle control for 45 min prior irradiation
with 4 Gy. Glioblastoma and endothelial cells treated with 4 Gy
showed increased Akt activity (pAkt Ser-473) relative to Akt in
both lines. Treatment with 1µM PF-8380 prior to 4 Gy, however,
reduced Akt phosphorylation in both glioblastoma and endothe-
lial cell lines relative to treatment with 4 Gy alone (Figure 4).
With the exception of GL261 where total Akt levels decreased
with pre-treatment of PF-8380 without and with irradiation, Akt
and actin levels were relatively unaffected across all four cell
lines.
INHIBITION OF ATX ABROGATES RADIATION-INDUCED TUMOR
NEOVASCULARIZATION IN THE WINDOWMODEL
ATX has been implicated in angiogenesis, with the enzyme
linked to the up-regulation of pro-angiogenic factors, such as
VEGF (45). To study the effect of inhibition of ATX on tumor-
associated angiogenesis, a dorsal window model experiment was
performed. Following 4 Gy irradiation, tumor-associated vascular-
ity increased 27% (P = 0.382; Figure 5). Treatment with 10 mg/kg
PF-8380 increased tumor-associated vascularity modestly by 20%
(P = 0.497). When compared to control, treatment of PF-8380
45 min before 4 Gy irradiation decreased vascularity by nearly
48% when compared to control (P = 0.031) and by 65% when
compared to mice that received radiation alone (P = 0.011).
INHIBITION OF ATX DELAYS TUMOR GROWTH IN IRRADIATED GL261
MOUSE MODEL
To evaluate the efficacy of ATX inhibitor PF-8380 in vivo, a hetero-
topic GL261 mouse tumor model was used. GL261 cells (1× 106)
were injected subcutaneously in the right flank of the Nu/Nu mice.
Once the tumors were palpable, the tumor-bearing mice were ser-
pentine sorted so that the average tumor volumes were the same
in all the four treatment groups. Seven tumor bearing mice were
www.frontiersin.org September 2013 | Volume 3 | Article 236 | 5
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FIGURE 2 | Inhibition of ATX enhances radiation-induced cell death in
irradiated GBM cells (U87-MG and GL261) in co-culture with endothelial
cells (HUVEC and bEnd.3) monitored by clonogenic survival assays.
Human U87-MG and murine GL261 glioma cells were plated in co-culture
with corresponding HUVEC and bEnd.3 endothelial cells. Cells were treated
with 1µM PF-8380 () or DMSO (•) for 45 min and irradiated with 0, 2, 4, and
6 Gy. The cells were incubated for 7–10 days and colonies were fixed, stained
with 1% methylene blue, and colonies greater than 50 cells were counted.
Shown are the clonogenic survival curve and mean surviving fractions and
SEM; *P >0.05.
used for each treatment. Mice were either treated with vehicle
(DMSO) alone, irradiation alone (five fractions of 2 Gy daily),
10 mg/kg PF-8380 alone, or a combination of 10 mg/kg PF-8380
with irradiation (five fractions of 2 Gy). The endpoint for analysis
was based on the number of days taken to reach a tumor volume of
7000 mm3. Untreated mice reached this endpoint after 11.2 days,
while PF-8380 treated mice and mice treated with radiation alone
exhibited delayed tumor growth of 12.6 and 23.2 days, respec-
tively. Furthermore, mice treated with a combination of PF-8380
and radiation required more than 32 days before reaching the end-
point tumor volume (Figures 6A,B). Kruskal–Wallis and Tukey’s
pairwise comparisons showed a significant difference in number
of days taken to reach a tumor volume 7000 mm3 between irradi-
ation treated mice and mice treated with a combination treatment
of PF-8380 and irradiation (P < 0.05).
DISCUSSION
Multi-modal therapeutic strategies that integrate aggressive de-
bulking surgery with high dose radiation in combination with
TMZ have improved outcomes in glioblastoma. However the
radioresistance of these tumors renders these approaches inef-
fective in halting progression and recurrence in the majority of
patients (44). Glioblastoma remains highly resistant to radiation
therapy due to its mitogenic, migratory, invasive, and angiogenic
characteristics. The enhanced expression of ATX in glioblastomas
has been cited as a major contributor to its invasive properties,
which are mediated by the paracrine actions of the LPA pro-
duced by ATX (38). The discovery that radiation can trigger
the activation of ATX and LPA signaling provides a potential
explanation for the behaviors of glioblastoma in the therapeu-
tic response to radiation therapy (27). Extracellular secretion of
ATX from cancer cells following irradiation leads to conversion
of LPC to LPA due to its lysoPLD activity. LPA then binds to G-
protein coupled receptors (GPCRs), known as (46) LPA1–6 which
function to promote events such as cell survival and prolifer-
ation, especially in the nervous, vascular, immune, and repro-
ductive system, while also promoting tumor invasion and tumor
angiogenesis (38).
We have recently shown that inhibition of both ATX and LPA
receptors by Brp-LPA leads to inhibition of migration and tubule
formation in endothelial cells (28). Brp-LPA also repressed the
growth of GL261 in a heterotopic mouse tumor model. To further
characterize the relationship between ATX and tumor behavior
independent of LPA receptor blockade, we sought to determine
if inhibition of ATX alone would be sufficient to stall tumor
growth and progression. We used PF-8380, a specific chemical
inhibitor of ATX that has been shown to successfully inhibit lyso-
PLD enzyme activity in various inflammatory conditions, includ-
ing cancer, multiple sclerosis, and arthritis (40). In this study, we
found that inhibition of ATX by PF-8380 can significantly alter the
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FIGURE 3 | Inhibition of ATX attenuates cell migration in irradiated GBM
cells. Human glioma U87-MG (A) and mouse glioma GL261 cells (B) were
plated on 60 mm plates and allowed to grow to 70% confluency. A gash was
created, washed in PBS, and treated with vehicle (DMSO) or 1µM PF-8380
for 45 min before irradiation with 4 Gy. After 24 h, cells were fixed in 70%
EtOH and stained with methylene blue. Migrated cells were counted and
normalized to surrounding cell density per HPF. Shown are the bar graphs
(A,B) representing the mean percentages of migrating cells relative to
corresponding controls with SEM; *P > 0.05. Inhibition of autotaxin
attenuates cell invasion in irradiated glioblastoma cells. GL261 (C) and
U87-MG (D) cells were added to the eight micron inserts and were treated
with 1µM PF-8380 or DMSO for 45 min prior to irradiation with 4 Gy. Cells
were allowed to invade into the complete medium at the bottom of the
inserts for 48 h. Cells were fixed, stained, and cell invasion was calculated by
counting the number of cells per HPF. Shown are the bar graphs representing
the number of invasive cells with SEM; *P >0.05.
glioblastoma microenvironment, thereby abrogating the resistant
and invasive properties of glioblastoma and improving its response
to radiation therapy.
The rationale for using ATX as a potential therapeutic tar-
get is based on reports that ATX is over expressed in various
cancers including glioblastoma (38), lung cancer (47, 48), and
breast cancer (49), and that its activity contributes to its inva-
siveness and tumorigenesis. To establish the significance of ATX
in gliomblastoma models, we evaluated the expression levels of
ATX in glioblastoma and endothelial cells at both mRNA and
protein levels. Analysis of mRNA (Figures 1A,B) showed that
glioma cell cells had higher expression ATX when compared to
endothelial cells. We found that inhibition of ATX using PF-8380
in serum free media (Figure 2) reduced the clonogenicity of both
the gliomas and the endothelial cells. These results indicate that
inhibition of ATX is sufficient to prevent the formation of LPA
and its downstream interactions with the LPA receptors as we had
shown earlier (28).
We studied how ATX inhibition might influence cancer cell
behavior in vitro. Noting previous work identifying ATX derived
LPA as an essential stimulator of cancer cell invasion and migration
(29), we hypothesized that the overexpression of ATX in glioblas-
toma is pivotal to invasiveness and motility observed at the cellular
level. We performed migration and invasion assays in mouse
GL261 and human U87-MG glioblastoma with combinations
of PF-8380 and radiation. In wound healing assays, GL261 and
U87-MG cells pretreated with ATX inhibitor prior to irradiation
resulted in 17.9 and 33% decrease in cell migration in U87-MG
and GL261 respectively (Figures 3A,B). In the tumor cell inva-
sion assays, GL261 and U87-MG cells pretreated with PF-8380
prior to irradiation resulted in 50 and 35.6% decrease in cell inva-
sion in U87-MG and GL261 respectively (Figures 3C,D). These
results highlight a potential basis for the previous observations in
the overall suppression of tumor development in vivo after ATX-
inhibition (28). Furthermore, by illustrating significant reduction
in chemotaxis following inhibition of ATX and irradiation, we
have shown that ATX may play a major role in the development
of radioresistance and recurrence of glioblastoma. The enhanced
invasiveness and migration conferred by ATX activity may account
for the extension beyond resection/irradiation margins and the
subsequent evasion of therapy.
It has been shown that irradiating endothelial cells activates
cPLA2 and leads to production of LPC, which is then converted to
LPA by ATX (29–31). LPA in turn activates pro-survival pathways
such as the PI3K-Akt pathway (21–24). Akt has been implicated
with the radioresistance in glioblastoma (50) and is a down-
stream target of the commonly mutated RTK/RAS/PI3K pathway
in glioblastoma (18). Apart from its effects on tumor growth,
invasiveness, and angiogenesis, LPA is believed to play a major
role in the mediation of pro-survival signaling in the tumor
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FIGURE 4 | Inhibition of ATX reduces Akt Phosphorylation in GBM cells
grown in co-culture. U87-MG and GL261 glioma cells were plated in
co-culture with corresponding HUVEC and bEnd.3 endothelial cells. Cells
were treated with 1µM PF-8380 or DMSO for 45 min and irradiated with 4 Gy.
Cells were lysed 15 min after irradiation and cellular proteins were
immunoblotted using antibodies against pAktSer473/Thr308, total Akt, to analyze
levels of expression of these proteins. Actin was used to evaluate the protein
loading in each lane.
microenvironment (2). To determine the extent of ATX-derived
LPA involvement in cancer cell resilience, we examined the effects
of ATX inhibition on the activation of downstream pro-survival
pathways. Inhibition of ATX resulted in reduced Akt activity in
both U87-MG and GL261 after irradiation (Figure 4). This sup-
ports our observation of reduced colony formation, further linking
ATX to cancer cell survival in the setting of radiotherapy. Our
results also support the notion that LPA receptor activation by LPA
represents a pathway for PI3K-Akt activation in glioblastoma.
While signaling at LPA receptors promotes the invasive and
migratory characteristics of glioblastoma, LPA receptor activation
in endothelial cells is known to promote neovascularization and
tubule formation (28). However in the setting of radiation therapy,
LPA receptor signaling is likely to result from activation of cPLA2.
The important role of ATX in the formation and stabilization of
blood vessels is highlighted in ATX−/− knockout mice, which are
embryonic lethal at ∼E9 and have severe vascular defects in the
yolk sac (51). To study the effect of ATX inhibition on radiation-
induced neovascularization, and to elucidate if LPA production by
ATX is pivotal for the angiogenic response to radiation, we used
a mouse tumor vascular window model to study the changes in
tumor vascularity in response to combinations of radiation and
PF-8380. We found that radiation triggered a slight increase in
neovascularization, however pre-treatment with PF-8380 resulted
in significant reduction in vascularity (Figure 5). The action of
LPA generated by ATX on the tumor-endothelium appears to
be critical for the normal response to radiation. This supports
previous work where concurrent inhibition of ATX and LPA recep-
tors was shown to reduce endothelial cell invasion, migration,
and survival post-irradiation (28). However, this also indicates
that inhibition of ATX may be sufficient to stifle angiogenesis in
radioresistant gliomas. This observation, together with previous
studies linking intracellular LPC to neovascularization in irradi-
ated tumors, presents new relevance of LPA receptor mediated
signaling downstream of cPLA2 and ATX activation in the vascular
response.
In light of the anti-angiogenic effects of ATX inhibition
observed in the vascular window model, and studies linking the
overexpression of ATX in glioblastoma to its overall pathology (1,
30), we hypothesized that inhibition of ATX mediated LPA pro-
duction in the tumor microenvironment would delay the tumor
growth. We used a syngeneic mouse GL261 brain tumor model
to evaluate if ATX inhibitor PF-8380 could serve as a therapeutic
modality. Mice treated with PF-8380 prior to irradiation signif-
icantly delayed tumor growth when compared to mice treated
with radiation alone (Figure 6). When compared to the untreated
mice (DMSO), it took 12 additional days to attain a tumor vol-
ume of 7000 mm3 when the mice were treated with irradiation
alone. When compared to irradiation alone it took eight addi-
tional days to attain a tumor volume of 7000 mm3 when the mice
were treated with PF-8380 and irradiation. Mice when treated with
PF-8380 and irradiation took 20.8 additional days for the tumor to
attain a volume of 7000 mm3 when compared to untreated mice.
Mice treated with ATX inhibitor alone did not show significant
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FIGURE 5 | Inhibition of ATX abrogates radiation induced tumor
neovascularization. The animals were implanted with diffusion chambers
containing GL261 cells. Seven days after implantation, the mice were
treated with 10 mg/Kg PF-8380 or DMSO for 30 min prior to irradiation
(3 Gy). After 14 days of implantation, the animals were sacrificed and the
skin fold covering the diffusion chamber was observed. Shown are the
representative micrographs showing the tumor induced neovasculature
(black arrow) and preexisting vasculature (red arrow) and the bar graph
depicting the mean number of neovasculature (>10 field for each mouse)
SEM from each treatment group of five mice; *P < 0.05.
delay in tumor delay compared to untreated control. Mice treated
with PF-8380 alone delayed tumor growth by 1.4 days to reach
a tumor volume of 7000 mm3 compared to untreated control,
suggesting that the role of ATX in tumor growth is linked to
the radiation stress response (22, 46). These results indicate that
the combination of ATX inhibition and irradiation can suppress
tumor growth, thereby highlighting ATX as a molecular target in
the radiosensitization of brain tumors.
In summary, the findings of this study suggest that ATX plays
a pivotal role in translating the activation of cPLA2 by ioniz-
ing radiation into responses observed in the glioblastoma and
endothelium. We found that inhibition of ATX with PF-8380
resulted in reduced production of LPA and disruption of down-
stream effects on glioblastoma cells in vivo and in vitro. In this
study, inhibition of ATX prior to irradiation was sufficient to
FIGURE 6 | Inhibition of ATX in combination with irradiation delays
tumor growth in a heterotopic tumor model of GL261. GL261 cells
were implanted into the hind limbs of nude mice. Mice were treated for five
consecutive days with PF-8380 or vehicle control prior to irradiation. Tumors
were irradiated with 2 Gy for five consecutive days for a total of 10 Gy.
Shown is a line graph depicting the mean tumor volumes with SEM from
each treatment group of 10 mice *p<0.05 (A). The box plot depicting the
tumor growth delay calculated as the number of days for tumors to reach
7000 mm3 (B).
delay tumor growth, inhibit cell invasion, migration, and neo-
vascularization, while also reducing survival of cancer cells. These
findings, together with previous work highlighting the importance
of LPA mediated signaling in tumor growth and cell survival, iden-
tify ATX as a viable molecular target for the radiosensitization of
glioblastoma and destruction of the tumor vascular network.
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